Nomegestrol acetate for symptomatic endometriosis and meningioma risk: understandable statistics for decision-making

Eur J Obstet Gynecol Reprod Biol. 2023 Jul:286:149-150. doi: 10.1016/j.ejogrb.2023.05.002. Epub 2023 May 6.

Authors

Paolo Vercellini¹, Giovanna Esposito², Claudia Santucci³, Fabio Parazzini³, Carlo La Vecchia³

Affiliations

¹ Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy.
² Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Italy. Electronic address: giovanna.esposito@unimi.it.
³ Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Italy.

PMID: 37183159
DOI: 10.1016/j.ejogrb.2023.05.002

No abstract available

Publication types

Letter

MeSH terms

Endometriosis* / drug therapy
Female
Humans
Megestrol
Meningeal Neoplasms*
Meningioma*
Norpregnadienes*

Substances

nomegestrol acetate
Megestrol
Norpregnadienes